ZM323881|2mg|K1289-上海高创化学科技有限公司

SKU:K1289		M. Wt:411.86
Formula:C22H18FN3O2.HCl		Solubility:DMSO 10 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Purity:99%		Storage:2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
CAS No.:193000-39-4		Synonyms:N/A
Chemical Name4-fluoro-2-methyl-5-[(7-phenylmethoxyquinazolin-4-yl)amino]phenol

Description	ZM323881 inhibits VEGF-A-induced endothelial cell proliferation with IC50 of 8 nM.
Targets	VEGFR2
IC50	2 nM
In vitro	ZM323881 inhibits VEGF-A-induced endothelial cell proliferation with IC50 of 8 nM and VEGF-R2 tyrosine phosphorylation in vitro. VEGF-A-mediated increases in vascular permeability in perfused mesenteric microvessels in vivo can be reversibly abolished by ZM323881. ZM323881 inhibits activation of VEGFR-2, but not of VEGFR-1, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), or hepatocyte growth factor (HGF) receptor. SCC-9 cells express the VEGF receptors Flk-1 and neuropilin-1 (Np-1), with VEGF treatment increasing VEGF promoter activity and VEGF secretion that was attenuated by the Flk-1 tyrosine kinase inhibitor, ZM 323881. VEGF significantly increases VEGF promoter activity. Treatment of cells with the ﬂk-1 tyrosine kinase inhibitor ZM323881 completely blocks this effect. VEGF can stimulate Hif-1alpha protein accumulation was blocked by treatment with ZM323881. The effects of ZM 323881 were speciﬁc based on its lack of effect on IGF-1 stimulated Hif-1alpha accumulation. ZM 323881 treatment alone reduces the basal expression of Hif-1alpha, consistent with the presence of a VEGF: VEGFR-2 autocrine loop in quiescent SCC-9 cells.
In vivo	N/A.
Clinical Trials	N/A
Features	N/A

Description

ZM323881 inhibits VEGF-A-induced endothelial cell proliferation with IC50 of 8 nM.

Targets

VEGFR2

IC50

2 nM

In vitro

ZM323881 inhibits VEGF-A-induced endothelial cell proliferation with IC50 of 8 nM and VEGF-R2 tyrosine phosphorylation in vitro. VEGF-A-mediated increases in vascular permeability in perfused mesenteric microvessels in vivo can be reversibly abolished by ZM323881. ZM323881 inhibits activation of VEGFR-2, but not of VEGFR-1, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), or hepatocyte growth factor (HGF) receptor. SCC-9 cells express the VEGF receptors Flk-1 and neuropilin-1 (Np-1), with VEGF treatment increasing VEGF promoter activity and VEGF secretion that was attenuated by the Flk-1 tyrosine kinase inhibitor, ZM 323881. VEGF significantly increases VEGF promoter activity. Treatment of cells with the ﬂk-1 tyrosine kinase inhibitor ZM323881 completely blocks this effect. VEGF can stimulate Hif-1alpha protein accumulation was blocked by treatment with ZM323881. The effects of ZM 323881 were speciﬁc based on its lack of effect on IGF-1 stimulated Hif-1alpha accumulation. ZM 323881 treatment alone reduces the basal expression of Hif-1alpha, consistent with the presence of a VEGF: VEGFR-2 autocrine loop in quiescent SCC-9 cells.

In vivo

N/A.

Clinical Trials

N/A

Features

N/A

工商信息

企业名称

上海高创化学科技有限公司

企业信息已认证

企业类型

信用代码

310228001353263

成立日期

2010-06-05

注册资本

经营范围

从事化学科技、计算机领域内技术开发、技术咨询、技术服务,从事生物科技领域内技术开发、技术咨询,化学试剂、化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备(除医疗器械),仪器仪表,Ⅰ类医疗器械,金属制品,电子产品,机电产品销售。【依法须经批准的项目,经相关部门批准后方可开展经营活动】

ZM323881由上海高创化学科技有限公司为您提供，货号K1289，规格：2mg，CAS号：193000-39-4，如您想了解更多关于ZM323881价格、ZM323881结构式、批发、用途等信息，欢迎咨询。除供应ZM323881外，还可为您提供重组人半乳糖凝集素16/LGALS16 Human、含铁牛血清（新西兰）、Gibco山羊血清（新西兰）等试剂，公司有专业的客户服务团队，是您值得信赖的合作伙伴，上海高创客户服务电话，售前、售后均可联系。